

State of Oklahoma SoonerCare



Bosulif[®] (bosutinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:	
Drug Information			
Pharmacy Billing (NDC:) Start Date (or date of next dose):		
Dose:			
Pharmacy Information			
Pharmacy NPI:	Pharmacy Name:		
Pharmacy Phone:	Pharmacy Fax:		
Prescriber Information			
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	_ Prescriber Fax:	Specialty:	
Criteria			
Chronic Myeloid Leukemia (CML) A. Chronic, accelerated, or blast phase CML? Yes No B. Newly diagnosed or resistant/intolerant to other Tyrosine Kinase Inhibitors TKIs)? Yes No Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) A. Used as upfront therapy (including induction and consolidation) in combination with multi-agent chemotherapy or a single agent? Yes No As a single agent and unfit for additional therapies As a single agent and unfit for additional therapies In combination with vincristine and prednisone, with or without methotrexate and mercaptopurine Post-hematopoietic stem cell transplant C. Used as a single agent or in combination with multi-agent chemotherapy for relapsed/refractory disease? Yes No D. Does member have any of the following mutations of BCR-ABL1: T315I, V299L, G250E, F317L? Yes No Other: Additional Information:			

(Page 1 of 2)

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-90 4/23/2025



State of Oklahoma SoonerCare



Bosulif[®] (bosutinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Criteria	
3. Has the member experienced	ence of progressive disease while o	I to bosutinib therapy? Yes No
Additional Information:		
	(Page 2 of 2)	

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Date:

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

Prescriber Signature:

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-90 4/23/2025